This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Analysis of effectiveness
The analysis of the clinical study was based on the intention to treat principle. The primary health outcomes used in the study included the rate of in-hospital mortality, rate of recurrent ischemia and stroke, rate of non-protocol catheterization, rate of non-protocol PTCA, number of CABG or CHF, cardioversion of defibrillation, IABC, intubation, major bleeding, blood transfusion, vascular surgical repair, number of catheterization procedures per patient, number of PTCA procedures per patient, predischarge exercise test, length of hospital stay, postdischarge events and the number of patients alive and free of discharge at late follow-up. There were no significant differences in baseline demographic or clinical features on presentation between the two patient groups. These features included age, gender, history of diabetes mellitus, hypertension or hypercholesterolemia, cigarette smoking, previous myocardial infarction or congestive heart failure, time from symptom onset to randomisation, anterior myocardial infarction, admission Killip class >2, admission systolic blood pressure and admission heart rate.
Effectiveness results
Compared with the t-PA group, patients treated with primary PTCA exhibited lower rates of in-hospital death (4 versus 13, p=0.03), rate of reinfarction (5 versus 13, p=0.06), rate of death or nonfatal reinfarction (9 versus 24, p=0.008), rate of recurrent ischemia (20 versus 52, p<0.0001), rate of stroke (0 versus 9, p=0.02), rate of non-protocol catheterization (23 versus 114, p<0.0001), rate of non-protocol PTCA (11 versus 65, p<0.0001), number of catheterization procedures per patient (1.15 +/-0.43 versus 0.71 +/-0.6, p<0.0001), number of PTCA procedures per patient (0.96 +/-0.37 versus 0.41 +/-0.59, p<0.0001) and hospital stay (7.6 +/-3.3 days versus 8.4 +/-4.7 days, p=0.04).
Events during the follow-up period occurred with similar frequency in patients initially assigned to t-PA and PTCA, although trends were present for a greater late incidence of non-elective hospitalisation and late bypass surgery in PTCA patients. For the two groups, hospital stay after discharge was 60 versus 42 days, (p=0.06), and the number of CABGs was 22 versus 11, (p=0.06) respectively.146 of 177 PTCA patients and 134 of 180 t-PA patients were alive and free of reinfarction at the end of the follow-up period. For the non-high risk patients, PTCA resulted in discharge 1.3 days earlier (hospital stay of 7.0 days +/-3.1 versus 8.3 +/-4.5, p=0.03) and lowered the rate of recurrent ischemia (9 versus 27, p=0.0007), the number of non-protocol catheterisations (7 versus 55, p<0.0001) and the number of nonprotocol PTCA (4 versus 33, p<0.0001). In high-risk patients, PTCA markedly reduced in-hospital mortality rates (2 versus 10, p=0.01), rate of recurrent ischemia (11 versus 25, p=0.01), rate of stroke (0 versus 6, p=0.03), the number of non-protocol catheterisations (16 versus 59, p<0.0001) and the number of non-protocol PTCA (7 versus 32, p<0.0001).
Clinical conclusions
If patients with AMI present at centres with skilled PTCA operators, primary PTCA can be expected to save lives and lower the incidence of non-fatal reinfarction and stroke compared with treatment with thrombolytic therapy.
Measure of benefits used in the economic analysis
No explicit measure of benefit was put forward. Primary benefit measures include the rate of in-hospital mortality, recurrent ischemia, stroke, hospital stay and the number of patients alive and free of reinfarction at late follow-up.
Direct costs
Three categories of costs were assessed: hospital charges, professional cardiology and cardiac surgery fees, and postdischarge follow-up resource consumption. Costs were not discounted. Costs and quantities were not reported separately. The quantity/cost boundary adopted was that of the hospital. The estimation of costs and quantities was based on actual data. For the case of follow-up costs, late resource consumption was approximated by tabulating hospital readmissions and major clinical events during the first 2 years after discharge. Hospital and physician bills
